Navigation Links
Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Date:12/5/2007

with moderate to severe DN.

-- Dow AgroSciences has the option to exercise a commercial license for

the use of our ZFP technology in plant agriculture in the second half

of 2008.

-- The Phase 2 trial that Sangamo plans to initiate in the first quarter

of 2008 evaluating the mobilization of aldehyde bright stem cells in

subjects with diabetic neuropathy after treatment with the SB-509.

-- Plans for a Phase 2 trial of SB-509 for the treatment of ALS will also

be outlined at the briefing. Sangamo expects to initiate this trial in

the first half of 2008.

-- Plans to initiate a Phase 1 trial of a ZFP Therapeutic to treat

glioblastoma in the first half of 2008 and a Phase 1 trial for a ZFP

Therapeutic to treat HIV infection in the second half of 2008.

-- Sangamo expects to report data from the Phase 1 clinical programs in

critical limb ischemia, the severe form of peripheral artery disease in

2008.

-- Sangamo estimates that it expects to end 2008 with approximately $55M

in cash and cash equivalents, based on current expense projections and

expected progress in existing corporate relationships.

The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website until December 20, 2007 and is available at via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Walter and Eliza Hall Institute scientists have revealed ... in the immune system, identifying in the process ... disorders. Dr Jeff Babon and Professor Nick ... and Haematology divisions respectively, study interactions between internal ...
... wallpaper-like liner help reduce the number of cases of malaria, ... Shepard, a professor at the Schneider Institutes for Health Policy ... gotten the Bill and Melinda Gates Foundation to help. A ... allow Shepard and collaborators to pursue their research in Kenya ...
... , THURSDAY, Feb. 16 (HealthDay News) -- Researchers have sequenced ... and the transmissible facial cancer that threatens the species with ... meat-eating marsupials found only on the Australian island of Tasmania, ... the journal Cell . "There are targeted drugs ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers have discovered ... of cases of inherited dilated cardiomyopathy, a serious heart muscle ... In the study, published in the Feb. 16 issue ... analyzed the DNA of 312 people with dilated cardiomyopathy, 231 ...
... parent-training program is effective in reducing the risk of low-income, ... found that after one year, there was a 9 percent ... group, while a control group that did not receive the ... obese children. "This is the first ...
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
Cached Medicine News:Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:Gates Foundation awards grant to tackle malaria 2Health News:Genome Map Might Help Save Tasmanian Devil From Extinction 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 3Health News:Parent-training intervention curbs pediatric obesity rates, study shows 2Health News:Parent-training intervention curbs pediatric obesity rates, study shows 3Health News:Gene Linked to Start of Puberty 2
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LigoCyte Pharmaceuticals, Inc. , a private, clinical-stage ... vaccine products, announced today that it has initiated ... (IM) norovirus vaccine candidate, marking the fourth human ... (VLP) vaccine program.  The Phase I dose-escalation study ...
... Top researchers at the Gastrointestinal Cancer Research Lab at ... clinical applications of BCM-95®, a new patented extract of ... Previous studies have shown that BCM-95 curcumin was 7-10 ... had a retention time in the bloodstream between 8 ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2